Liquid Biopsy Test: Protocol and Steps
Learn which advanced tools are most used to isolate and analyze the main liquid biopsy targets.
In this article, explore some of the advanced molecular techniques that are most used for detecting the main biomarkers involved in liquid biopsy.
Contents
How does a liquid biopsy work?
Liquid biopsy protocol and steps
How does a liquid biopsy work?
A liquid biopsy consists of the isolation and characterization of tumor-derived materials – such as intact cancer cells or nucleic acids – in a sample of body fluid collected from a cancer patient to gain information about their disease.1
Since most tumors are in contact with the bloodstream, liquid biopsies often involve blood sample analysis – but other sources of body fluids include urine, stool, saliva, pleural fluid, cerebral spinal fluid and peritoneal fluid or washings.2
Liquid biopsy targets
The list of potential tumor-derived materials that can be analyzed in a liquid biopsy includes:
- Circulating tumor cells (CTCs)3 – intact cancer cells shed by both primary and metastatic tumors.
- Circulating cell-free DNA (cfDNA)4 and circulating tumor DNA (ctDNA)4 –fragments of DNA released from cells (cfDNA), and the tumor-derived DNA fraction (ctDNA).
- Extracellular vesicles (EVs)5– small membrane-bound vesicles, including micro-vesicles and exosomes, which can carry cargo – such as nucleic acids and proteins – during tumor metastasis.
- Circulating cell-free RNA (cfRNA)6 – cancer-related messenger RNAs or non-coding RNAs, including microRNAs (miRNAs).
Figure 1:
The tumor-derived materials that liquid biopsy can detect.
Credit: Technology Networks
Liquid biopsy protocol and steps
Liquid biopsy protocols are focused on the rapid detection of clinically relevant information with high sensitivity, selectivity and specificity while remaining minimally invasive.
The techniques selected for a liquid biopsy will depend on the nature of the target. For instance, it may involve the isolation, enumeration and characterization of CTCs – or the isolation and molecular analysis of other tumor-derived materials.
CTCs
1. Isolation
Over the last decade, several technologies have emerged that aim to isolate and separate CTCs from the massive pool of circulating blood cells – and then count and characterize them.3 Each of these approaches exploits a key difference that discriminates CTCs from normal blood cells (such as differential gene/protein expression, morphology, volume or biophysical properties) to enable the sensitive selection and capture of these very rare cells. They include:
Immune-based detection methods – these are the most widely used approaches and use antibodies to selectively bind cell-surface antigens that discriminate CTCs from blood cells. These antibodies may be conjugated to magnetic nanoparticles7 or immobilized on the walls of microfluidic chips8 to isolate CTCs. A new generation of CTC antigen-based dual modality platforms combines immunomagnetic beads with microfluidics.
- Size-dependent isolation techniques – including filtration, microfluidics, centrifugation and inertial focusing.
- Direct imaging – imaging-based detection methods use specific fluorescent tags to identify and count CTCs in blood. Each of these technologies is unique in its sample preparation, detection algorithms and fluorophores.
- Dielectrophoresis9 – which relies on particles with different polarization that move differently under a non-uniform electric field.
2. Enumeration
Understanding DNA Methylation Analysis for Modern Oncology Research
This eBook explores the major methods used to study DNA methylation, comparing traditional bisulfite conversion with methylation-sensitive restriction enzyme (MSRE) workflows.View eBook
The methods used to count the number of CTCs detected in a sample include impedance10, high-throughput imaging11, flow cytometry12 and artificial intelligence.
3. Characterization
Techniques used to characterize CTCs include immunostaining, fluorescent in situ hybridization (FISH), sequencing, quantitative reverse-transcription polymerase chain reaction (qRT-PCR), expression analysis and cell culture.3
EVs
The clinical application of EVs detected by liquid biopsy has so far been limited by the lack of simple, efficient procedures to obtain EVs with high purity.13 Some of the major strategies used to isolate these extracellular vesicles include ultracentrifugation, polymer precipitation, ultrafiltration, size-exclusion chromatography, affinity isolation and microfluidics-based techniques.13 Each of these approaches has its advantages and disadvantages.
cfDNA/ctDNA
Several methods have been used to quantify and detect tumor mutations in cfDNA/ctDNA14 – including droplet digital PCR15, beads emulsion, amplification and magnetics (BEAMing)16, next-generation sequencing-based approaches17 (whole exome or whole genome sequencing), cancer personalized profiling by deep sequencing (CAPP-seq)16 and tagged-amplicon deep sequencing (TAm-Seq).18 The profiling of epigenetic features of ctDNA, such as methylation signatures19, may provide information about the tissue of origin.
cfRNA
Profiling circulating cell-free (cfRNA) offers unique opportunities to detect cancer, predict the tumor of origin, and determine the molecular subtype.20 But technical and biological variability, coupled with a lack of standardized protocols, have so far hindered the clinical development of RNA-based liquid biopsies.21
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
